Nuran Günay
Research Subjects
Nuran Günay has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Adem Aktan
Department of Cardiology, Mardin Artuklu University, Mardin, Turkey
1 shared publication Adnan Duha Cömert
1 shared publication- Ahmet Ferhat Kaya
Department of Cardiology, Van Regional Education and Research Hospital, Van, Turkey
1 shared publication - Ahmet Genç
ANTALYA EĞİTİM VE ARAŞTIRMA HASTANESİ, KARDİYOLOJİ
1 shared publication - Ahmet Lütfullah Orhan
University of Health Sciences Türkiye, Sultan 2. Abdulhamid Han Training and Research Hospital, Clinic of Cardiology, İstanbul, Türkiye
1 shared publication Ahmet Serdar Yılmaz
1 shared publication
Latest Publications
- 15 November 2025
- Published by Elsevier in Clinical Radiology
- Vol. 92, 107176
Temporal patterns of diastolic and systolic dysfunction in hypertrophic cardiomyopathy assessed by cardiac magnetic resonance (CMR) time-volume parameters
- 15 November 2025
- Published by Elsevier in Clinical Radiology
- Vol. 92, 107176
Temporal patterns of diastolic and systolic dysfunction in hypertrophic cardiomyopathy assessed by cardiac magnetic resonance (CMR) time-volume parameters
- Open Access
- 25 September 2022
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 5 (5) , 1449-1455
Evaluation of cardio-pulmonary functions of previously healthy adults with moderate-severe COVID-19 pneumonia after discharge
Aim: Persistent dyspnea is one of the most frequent post-COVID symptoms. We aimed to evaluate the cardiopulmonary functions of COVID-19 survivors with moderate to severe COVID-19 pneumonia without comorbidity, during the first wave of pandemics. Material and Method: The study was conducted retrospectively in a single center. The electronic data of patients applied with dyspnea one month after hospital discharge, without any comorbidities, and who were evaluated with pulmonary function test (PFT) and echocardiography were included in the study. A total of adult 88 patients who suffered from COVID-19 pneumonia (46 moderate and 42 severe) were enrolled. Results of biochemical, hematological and radiological examinations, PFT parameters and echocardiography were recorded and compared between moderate and severe cases. Results: The mean age of 88 patients included in the study was 48±13 years. Sixty-seven (74.4%) of the patients were male. Pulmonary thromboembolism was not detected in both groups. PFT parameters performed were similar in the two groups and there was no statistically significant difference. Pulmonary function test of the patients with moderate COVID-19 pneumonia revealed mild restriction in 21.7% and moderate restriction in 2% of the patients. In the severe group, 38.1% of the patients had mild and 4.8% of the patients had a moderate restrictive pattern. Small airway obstruction was detected in 37% of the moderate group and in 38.1% of the severe group. Conventional echocardiographic parameters of the two groups were normal. Pulmonary arterial pressures were 22.6±8.3 vs 22.1±6.8; p=0.8 was found. Tricuspid annular plane systolic excursion were within normal limits. Conclusıon: The persistent dyspnea following COVID-19 pneumonia may be related to disturbances in PFT even in patients without comorbidities. We concluded that; the detailed evaluation of the patients with prolonged respiratory symptoms might help to detect the cardiopulmonary functional disturbances.
- 25 September 2022
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 5 (5) , 1449-1455
Open AccessEvaluation of cardio-pulmonary functions of previously healthy adults with moderate-severe COVID-19 pneumonia after discharge
Aim: Persistent dyspnea is one of the most frequent post-COVID symptoms. We aimed to evaluate the cardiopulmonary functions of COVID-19 survivors with moderate to severe COVID-19 pneumonia without comorbidity, during the first wave of pandemics. Material and Method: The study was conducted retrospectively in a single center. The electronic data of patients applied with dyspnea one month after hospital discharge, without any comorbidities, and who were evaluated with pulmonary function test (PFT) and echocardiography were included in the study. A total of adult 88 patients who suffered from COVID-19 pneumonia (46 moderate and 42 severe) were enrolled. Results of biochemical, hematological and radiological examinations, PFT parameters and echocardiography were recorded and compared between moderate and severe cases. Results: The mean age of 88 patients included in the study was 48±13 years. Sixty-seven (74.4%) of the patients were male. Pulmonary thromboembolism was not detected in both groups. PFT parameters performed were similar in the two groups and there was no statistically significant difference. Pulmonary function test of the patients with moderate COVID-19 pneumonia revealed mild restriction in 21.7% and moderate restriction in 2% of the patients. In the severe group, 38.1% of the patients had mild and 4.8% of the patients had a moderate restrictive pattern. Small airway obstruction was detected in 37% of the moderate group and in 38.1% of the severe group. Conventional echocardiographic parameters of the two groups were normal. Pulmonary arterial pressures were 22.6±8.3 vs 22.1±6.8; p=0.8 was found. Tricuspid annular plane systolic excursion were within normal limits. Conclusıon: The persistent dyspnea following COVID-19 pneumonia may be related to disturbances in PFT even in patients without comorbidities. We concluded that; the detailed evaluation of the patients with prolonged respiratory symptoms might help to detect the cardiopulmonary functional disturbances.
- 6 April 2022
- Published by Academician Publishing
Kardiyolojide Güncel Kanıtlarla Vaka Yönetimi
- Open Access
- 28 March 2022
- Published by Archives of Clinical and Experimental Medicine in ARCHIVES OF CLINICAL AND EXPERIMENTAL MEDICINE
- Vol. 7 (1) , 6-10
COVID-19 Pnömonili Hastaların Taburculuk Sonrası Sağ Ventrikül Fonksiyonunun Sağ Ventriküler Erken Giriş-Çıkış İndeksi ile Değerlendirilmesi
Aim The coronavirus disease 2019 (COVID-19) causes many cardiovascular complications. In patients with comorbidities, COVID-19 infection has a more severe course. Although some patients who do not have comorbidities, severe infection and death may occur. In studies, many echocardiographic parameters were found to be impaired in patients with COVID-19 pneumonia. The right ventricular premature inflow-output flow (RVEIO) index is a possible and indirect predictor of the severity of right ventricular dysfunction. The aim of our study is to evaluate the RVEIO index after discharge in patients with moderate-to-severe COVID-19 pneumonia without comorbidities. Methods The study was conducted in a single center, prospectively. One month after discharge, echocardiography and biochemical tests were performed in 57 patients with moderate-to-severe COVID-19 pneumonia without comorbidities. Results Pulmonary artery diameter was found to be significantly larger in the severe group [1.9 (1.8-2) vs. 2 (1.9-2.1); p=0.014]. Pulmonary artery acceleration time [140.92±11.70 vs 114.58±12.03; p=0.001)] and RVOT VTI [23.48±1.96 vs 19.18±2.2; p
- 28 March 2022
- Published by Archives of Clinical and Experimental Medicine in ARCHIVES OF CLINICAL AND EXPERIMENTAL MEDICINE
- Vol. 7 (1) , 6-10
Open AccessCOVID-19 Pnömonili Hastaların Taburculuk Sonrası Sağ Ventrikül Fonksiyonunun Sağ Ventriküler Erken Giriş-Çıkış İndeksi ile Değerlendirilmesi
Aim The coronavirus disease 2019 (COVID-19) causes many cardiovascular complications. In patients with comorbidities, COVID-19 infection has a more severe course. Although some patients who do not have comorbidities, severe infection and death may occur. In studies, many echocardiographic parameters were found to be impaired in patients with COVID-19 pneumonia. The right ventricular premature inflow-output flow (RVEIO) index is a possible and indirect predictor of the severity of right ventricular dysfunction. The aim of our study is to evaluate the RVEIO index after discharge in patients with moderate-to-severe COVID-19 pneumonia without comorbidities. Methods The study was conducted in a single center, prospectively. One month after discharge, echocardiography and biochemical tests were performed in 57 patients with moderate-to-severe COVID-19 pneumonia without comorbidities. Results Pulmonary artery diameter was found to be significantly larger in the severe group [1.9 (1.8-2) vs. 2 (1.9-2.1); p=0.014]. Pulmonary artery acceleration time [140.92±11.70 vs 114.58±12.03; p=0.001)] and RVOT VTI [23.48±1.96 vs 19.18±2.2; p
- 8 February 2021
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 37 (6) , 1883-1890
The effect of moderate and severe COVID-19 pneumonia on short-term right ventricular functions: a prospective observational single pandemic center analysis
It has been reported that myocardial damage and heart failure are more common in COVID-19 patients with severe symptoms. The aim of our study was to measure the right ventricular functions of COVID-19 patients 30 days after their discharge, and compare them to the right ventricular functions of healthy volunteers. Fifty one patients with COVID-19 and 32 healthy volunteers who underwent echocardiographic examinations were enrolled in our study. 29 patients were treated for severe and 22 patients were treated for moderate COVID-19 pneumonia. The study was conducted prospectively, in a single center, between 15 May 2020 and 15 July 2020. We analyzed the right ventricular functions of the patients using conventional techniques and two-dimensional speckle-tracking. Right ventricular end-diastolic and end-systolic area were statistically higher than control group. The right ventricular fractional area change (RVFAC) was significantly lesser in the patient group compared to the control group. Tricuspid annular plane systolic motion (TAPSE) was within normal limits in both groups, it was lower in the patient group compared to the control group. Pulmonary artery pressure was found to be significantly higher in the patient group. Right ventricular global longitudinal strain (RV-GLS) was lesser than the control group (− 15.7 [(− 12.6)–(− 18.7)] vs. − 18.1 [(− 14.8)–(− 21)]; p 0.011). Right ventricular free wall strain (RV-FWS) was lesser in the patient group compared to the control group (− 16 [(− 12.7)–(− 19)] vs − 21.6 [(− 17)–(− 25.3)]; p < 0.001). We found subclinical right ventricular dysfunction in the echocardiographies of COVID-19 patients although there were no risk factors.
- 8 February 2021
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 37 (6) , 1883-1890
The effect of moderate and severe COVID-19 pneumonia on short-term right ventricular functions: a prospective observational single pandemic center analysis
It has been reported that myocardial damage and heart failure are more common in COVID-19 patients with severe symptoms. The aim of our study was to measure the right ventricular functions of COVID-19 patients 30 days after their discharge, and compare them to the right ventricular functions of healthy volunteers. Fifty one patients with COVID-19 and 32 healthy volunteers who underwent echocardiographic examinations were enrolled in our study. 29 patients were treated for severe and 22 patients were treated for moderate COVID-19 pneumonia. The study was conducted prospectively, in a single center, between 15 May 2020 and 15 July 2020. We analyzed the right ventricular functions of the patients using conventional techniques and two-dimensional speckle-tracking. Right ventricular end-diastolic and end-systolic area were statistically higher than control group. The right ventricular fractional area change (RVFAC) was significantly lesser in the patient group compared to the control group. Tricuspid annular plane systolic motion (TAPSE) was within normal limits in both groups, it was lower in the patient group compared to the control group. Pulmonary artery pressure was found to be significantly higher in the patient group. Right ventricular global longitudinal strain (RV-GLS) was lesser than the control group (− 15.7 [(− 12.6)–(− 18.7)] vs. − 18.1 [(− 14.8)–(− 21)]; p 0.011). Right ventricular free wall strain (RV-FWS) was lesser in the patient group compared to the control group (− 16 [(− 12.7)–(− 19)] vs − 21.6 [(− 17)–(− 25.3)]; p < 0.001). We found subclinical right ventricular dysfunction in the echocardiographies of COVID-19 patients although there were no risk factors.
- Open Access
- 1 January 2021
- Published by Galenos Yayinevi in Medeniyet Medical Journal
- Vol. 36 (1) , 1-6
Comparison of D-dimer Level Measured on Third Day of Hospitalization with Admission D-dimer Level in Predicting In-hospital Mortality in COVID-19 Patients
Objective: The present study aimed to compare the value of D-dimer measured on the 3rd day of hospitalization with admission D-dimer level in predicting in-hospital mortality in coronavirus disease 2019 (COVID-19) cases. Method: In total, 231 patients with COVID-19 disease were included in the study. D-dimer levels were estimated using immunoturbidimetric assay with normal range of 0-500 μg/mL. In the current research, the primary outcome was the in-hospital mortality. Results: In the present research, 39 (16.8%) COVID-19 cases died during the index hospitalization. In a multivariable analysis; age, D-dimer (3rd day) (OR: 1.00, 95% CI: 1.00-1.00, p<0.001), WBC count, and creatinine were independent predictors of the in-hospital death for COVID-19 cases. The ideal value of D-dimer level on the 3rd day of hospitalization was 774 μq/mL (area under curve (AUC): 0.903, 95% CI: 0.836-0.968; p<0.01) with sensitivity of 83.2% and specificity of 83.6%. It was noted that D-dimer level on the 3rd day of hospitalization had a higher sensitivity (83.2% vs 67.6%, respectively) and AUC value than that of D-dimer level on admission (0.903 vs 0.799, respectively). Conclusion: The main finding in this investigation was that D-dimer elevation on the 3rd of hospitalization is more sensitive predictor of in-hospital mortality than D-dimer elevation on admission in COVID-19 patients. Even though further investigations are needed to forecast precise prognosis in patients with COVID-19 disease in terms of D-dimer levels, we believe that D-dimer levels on the 3rd day of hospitalization have an enhanced potential to be used as a prognostic marker in routine clinical practice.
- 1 January 2021
- Published by Galenos Yayinevi in Medeniyet Medical Journal
- Vol. 36 (1) , 1-6
Open AccessComparison of D-dimer Level Measured on Third Day of Hospitalization with Admission D-dimer Level in Predicting In-hospital Mortality in COVID-19 Patients
Objective: The present study aimed to compare the value of D-dimer measured on the 3rd day of hospitalization with admission D-dimer level in predicting in-hospital mortality in coronavirus disease 2019 (COVID-19) cases. Method: In total, 231 patients with COVID-19 disease were included in the study. D-dimer levels were estimated using immunoturbidimetric assay with normal range of 0-500 μg/mL. In the current research, the primary outcome was the in-hospital mortality. Results: In the present research, 39 (16.8%) COVID-19 cases died during the index hospitalization. In a multivariable analysis; age, D-dimer (3rd day) (OR: 1.00, 95% CI: 1.00-1.00, p<0.001), WBC count, and creatinine were independent predictors of the in-hospital death for COVID-19 cases. The ideal value of D-dimer level on the 3rd day of hospitalization was 774 μq/mL (area under curve (AUC): 0.903, 95% CI: 0.836-0.968; p<0.01) with sensitivity of 83.2% and specificity of 83.6%. It was noted that D-dimer level on the 3rd day of hospitalization had a higher sensitivity (83.2% vs 67.6%, respectively) and AUC value than that of D-dimer level on admission (0.903 vs 0.799, respectively). Conclusion: The main finding in this investigation was that D-dimer elevation on the 3rd of hospitalization is more sensitive predictor of in-hospital mortality than D-dimer elevation on admission in COVID-19 patients. Even though further investigations are needed to forecast precise prognosis in patients with COVID-19 disease in terms of D-dimer levels, we believe that D-dimer levels on the 3rd day of hospitalization have an enhanced potential to be used as a prognostic marker in routine clinical practice.
- 1 April 2020
- Published by Galenos Yayinevi in Hamidiye Medical Journal
- Vol. 1 (1) , 29-35
Neutrophil-to-Lymphocyte Ratio for the Assessment of Long-term Mortality in Patients with Heart Failure
- 1 April 2020
- Published by Galenos Yayinevi in Hamidiye Medical Journal
- Vol. 1 (1) , 29-35
Neutrophil-to-Lymphocyte Ratio for the Assessment of Long-term Mortality in Patients with Heart Failure